医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Herbalife Honored with Consumer Protection Guarantee Award in Thailand

2013年05月04日 AM05:40
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Herbalife (NYSE: HLF) has been presented with a Consumer Protection Guarantee award in Thailand. The award is given by the Consumer Protection Board (OCPB), which operates under the supervision of the Office of the Prime Minister of Thailand.

Presented by the Prime Minister’s Office as part of the Thai Consumer Protection Day event, the award recognizes Herbalife’s commitment to consumer protection and its dedication to providing high quality nutrition products to Thai consumers.

The Consumer Protection Guarantee award also highlights Herbalife’s adherence to Thailand’s consumer’s protection law, and serves as testament to the company’s financial strength and operational transparency, both key indicators for the OCPB.

The Consumer Protection Guarantee program was initiated by the OCPB in 2012 with the ultimate goal of engendering consumer confidence in businesses across 26 major sectors in preparation for Thailand’s integration into the ASEAN Economic Community.

About Herbalife Ltd.

Herbalife Ltd. (NYSE:HLF) is a global nutrition company that sells weight-management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 80 countries to and through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains information about Herbalife, including financial and other information at www.herbalife.com.

CONTACT

Herbalife
Julian Cacchioli
213-745-0519
julianc@herbalife.com
or
Khun
Wandee Lerdsupongkit
+66 02 233 4329
pr@francomasia.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024